Introduction
Pancreatic cancer is the 11th most common cancer in the UK and accounts for over 7,700 deaths per year [1] . Despite current research and advances in understanding pancreatic cancer biology, imaging detection methods and improved surgical outcomes, the prognosis remains poor with a 5-year survival of around 10% in resected disease [2] .
Surgical resection continues to be the only intervention for potential cure in 15-20% of patients [3] , the remainder presenting with unresectable disease. Even following a potentially curative resection, recurrence rates are high owing to residual macroscopic disease [4] . In an effort to improve survival, more radical approaches to surgical resections including extended lymphadenectomy and total pancreatectomy have been attempted; however, these have failed to prove any demonstrable survival benefit [5] [6] [7] [8] [9] .
In the late 1960s and early 1970s, studies were published demonstrating tumor response following radiation or CRT in locally advanced disease deemed unresectable [10, 11] . Trials in advanced disease and also smaller trials of adjuvant therapy have provided the basis and demonstrated the feasibility of undertaking trials in pancreatic cancer. This has resulted in a remarkable increase in the completion of large trials in advanced and resectable pancreatic cancer. The role of adjuvant therapy in resected pancreatic cancer has been examined in several recent trials and it has been demonstrated that adjuvant chemotherapy significantly increases survival compared with surgery alone.
Chemoradiotherapy
Radiation therapy has been employed with the idea of controlling any residual macroscopic disease at the site of resection. Radiation treatment is combined with chemotherapy and routes employed include external beam radiotherapy or, less frequently, intraoperative radiotherapy (IORT).
The use of radiation treatment against pancreatic cancer has been controversial owing to the lack of trial evidence supporting any conclusive benefit in its use compared with surgery alone or supportive therapy alone.
Intraoperative Radiotherapy
External beam radiotherapy in pancreatic cancer poses significant problems with the toxic effects of irradiation to local structures, most notably the small bowel. The use of IORT can reduce this, allowing a high dose of radiation to be delivered to the tumor bed while avoiding other local structures. The use of IORT has not been investigated in any adequately powered randomized trial and current available trial evidence make it difficult to draw conclusions about its use. To date, most series published have been impeded by small numbers, variability of stage of disease included and lack of treatment standardization [12] [13] [14] [15] [16] . A small randomized trial failed to show any survival benefit of IORT in addition to surgery [17] . A review of the current evidence highlighted the inability to draw any definitive conclusions about its use in the adjuvant setting and, therefore, more investigation is required [18] .
External Beam Radiotherapy plus Chemotherapy
The use of external beam radiotherapy has been investigated in phase 3 randomized trials. One of the 1st prospective randomized trials evaluating the role of adjuvant CRT in the treatment of resected pancreatic adenocarcinoma was published by the Gastrointestinal Tumor Study Group (GITSG) in 1985 [19] .
The GITSG trial by Kalser and Ellenberg [19] randomized 43 patients to receive either 40-Gy radiotherapy with 5-fluorouracil (5-FU) followed by weekly 5-FU for up to 2 years (21 patients) or no adjuvant treatment (22 patients). The median survival was only 11 months in the no adjuvant therapy group compared with 20 months in the group that received chemoradiotherapy (CRT). As a result of this, the trial was terminated early. Initially the trial was designed to enroll 150 patients in order to have a 90% power to detect a doubling of survival time (recruitment was slow and limited to 43 patients over 8 years). Other difficulties with the trial included poor compliance and quality assurance, only 9% of patients completed the intended 2 years of chemotherapy and 32% had violations of the radiation therapy. As a result of these issues, the authors conducted a confirmatory treatment trial in which a further 30 patients were entered into the treatment group without randomization, with an overall median survival of 18 months and 2-year survival of 46%. Despite the extra patients, the trial was too small to demonstrate a statistically significant difference in survival curves.
The European Organisation for Research and Treatment of Cancer conducted a multicenter prospective randomized phase 3 trial of adjuvant CRT published in 1999. Klinkenbijl et al. [20] recruited 218 patients with pancreatic and ampullary cancers. Randomization was to either observation or radiotherapy with split course radiotherapy (40 Gy) and concurrent 5-FU. Overall median survival was 24.5 months in the adjuvant treatment group versus 19 months in the observation group (log-rank p = 0.208). When looking at the patients with pancreatic ductal adenocarcinoma alone, there was a trend for increased survival in the CRT group (17.1 months vs. 12.6; p = 0.099). A recent report [21] on the long-term survival of patients from this trial reaffirmed no difference in overall survival between the 2 groups (death rate ratio: 0.91, 95% CI: 0.68-1.23, p = 0.54). The patterns of recurrent disease observed in both arms of the trial were very similar, and in each case over 70% of patients had distant metastases. These findings, again, highlight the need for a systemic component when considering adjuvant therapy for pancreatic cancer. The limitations of this study can be identified as a lack of maintenance chemotherapy and a questionable statistical design that limited its ability to detect a benefit for adjuvant chemoradiation.
Two years prior to publication of the European Organisation for Research and Treatment of Cancer 40891 trial, the Johns Hopkins Hospital group retrospectively reviewed their experience in 174 patients [22] . The patients all had potentially curative resections and received either adjuvant CRT (modified from the GITSG trial: external beam radiotherapy to the pancreatic bed with prophylactic irradiation of the hepatic bed followed by 5-FU plus leucovorin) or no adjuvant therapy. The median survival in the treatment group was significantly improved when compared to the no adjuvant therapy group (19.5 vs. 13.5 months, p = 0.003).
The European Study Group for Pancreas Cancer (ES-PAC) carried out the 1st adequately powered randomized control trail to assess adjuvant therapy in pancreatic cancer. Patients were recruited between February 1994 and June 2000 in 61 centers in 11 countries. The trial accrued some 289 patients with a 2 ! 2 factorial design. Patients were recruited if they had histologically proven ductal adenocarcinoma of the pancreas which had been macroscopically resected, with no evidence of local spread or distant metastases. The design was a 2 ! 2 factorial trial, such that patients were randomized twice to either chemotherapy [bolus 5-FU 425 mg/m 2 plus folinic acid 20 mg/m 2 days 1-5, monthly for 6 cycles] or no chemotherapy, and to chemoradiation (20-Gy dose to the tumor given in 10 daily fractions over a 2-week period plus an intravenous bolus of 5-FU 500 mg/m 2 on each of the first 3 days of radiotherapy and again after a planned break of two weeks) or no chemoradiation. Adjuvant therapy was started as soon as possible after recovery from the surgery, and patients were followed up at 3-month intervals until death. Aside from the 2 ! 2 factorial design allocation, randomization outside this was also permitted to one of the main treatment comparisons (i.e. chemotherapy vs. no chemotherapy, CRT vs. no CRT) recruiting a further 252 patients (ESPAC-1 plus).
The results of the ESPAC-1 trial have been the subject of some controversy due largely to confusion over the 2 ! 2 trial design, but the results of both the 289 patients entered into both randomizations and the full cohort of patients have been published separately [23, 24] .
In the final analysis, the median survival was 15.9 months in the CRT arm and 17.9 months in the group who were not assigned to receive adjuvant therapy (p = 0.05). Estimated 5-year survival was 10% in the CRT arm compared to 20% in those who did not receive CRT (p = 0.05) ( table 1 ).
The lack of a survival advantage seen in the CRT arm may be due to delays in administering radiation in those who suffered postoperative complications. This therefore reduces the benefit of chemotherapy that is derived by administering it as soon as possible after resection. There are also arguments that the radiation given during the ESPAC-1 trial was substandard or not exposed to rigorous quality control; however, it should be noted that the survival in the individual groups are the same or superior to that observed in North American randomized studies.
Survival analysis for the individual treatment arms showed a benefit for adjuvant chemotherapy, but not for adjuvant CRT. The survival benefit was evident even in resection margin-positive (R1) patients.
From ESPAC-1, it is apparent that CRT not only had no survival advantage, but may also have had a detrimental effect by delaying the onset of chemotherapy after surgical resection, and thus may have had a confounding negative effect on the chemotherapy versus no chemotherapy randomization. This finding remains controversial, however, as many US centers continue to support adjuvant CRT as standard treatment [25] .
Corsini et al. [26] from the Mayo clinic published a retrospective review of their experience in 2008. They reviewed 472 consecutive patients who underwent resection from 1975 to 2005 with R0 resection margins. For patients receiving CRT, the median survival was 25.2 versus 19.2 for those with no adjuvant therapy (p = 0.001). This was despite the significantly increased risk factors in the treatment group-positive nodes, high histological grade and disease extension outside the pancreas (p = 0.001).
There have been 3 recent analyses of the US Surveillance Epidemiology and End Results (SEER) database In 2006, the Radiation Therapy Oncology Group (RTOG) published a phase 3 trial comparing pre-and post-CRT using 5-FU with this regime plus gemcitabine [29] . They recruited 538 patients with analysis restricted to 442. There was no statistically significant difference between the 2 arms with respect to overall survival, but it was noted in a subgroup analysis that patients with head of pancreas cancers had a 21% reduction in risk of death in the gemcitabine arm (HR: 0.79, 95% CI: 0.633-0.99, p = 0.047). In this study, overall there were significantly more grade 4 hematologic toxicity in the gemcitabine arm (CRT 2%, CRT + gemcitabine 14%, p = 0.001).
Chemotherapy
The most commonly used chemotherapeutic agent in pancreatic cancer has been 5-FU both in the adjuvant and advanced disease setting. Gemcitabine is now the main agent recommended based on a small randomized study that demonstrated a modest survival benefit when compared to 5-FU and current evidence from ESPAC-3 [30, 31] .
Systemic Chemotherapy
In 1993, Bakkevold et al. [32] ) and mitomycin C (6 mg/m 2 ), once every 3 weeks for 6 cycles compared to a control group. 61 patients were randomized to the adjuvant regimen of combination chemotherapy (30 patients) versus no adjuvant treatment (31 patients). Adjuvant treatment was associated with an increased median survival (23 months vs. 11 months; p = 0.04), but no difference in 2 year survival (p = 0.10). The study pooled both pancreatic and ampullary cancers. The main problem in this trial was the unacceptably high incidence of treatment-related toxicity; only 56% of the treatment group completed the chemotherapy regimen making compliance a major issue.
Takada et al. [33] conducted a trial between April 1986 and June 1992 addressing the issue of adjuvant chemotherapy. They recruited 508 patients with a variety of biliary cancers, with a subset of 173 patients with pancreatic cancer. Patients were assigned to either adjuvant chemotherapy (5-FU and mitomycin C) or observation. In the final analysis, there was no statistically significant difference in either arm for the end-points of disease-free survival, time to recurrence and 5-year survival. One possible reason for the poor performance of chemotherapy may be the route of administration of the agent 5-FU. In this trial oral 5-FU was used, which has poor efficacy compared with intravenous administration owing to hepatic metabolism.
Kosuge et al. [34] conducted a multicenter randomized trial evaluating 5-FU and cisplatin versus observation between 1992 and 2000, recruiting 89 patients. Inclusion was limited to those with R0 resection and only 2 cycles of chemotherapy were given. In this study there was no survival advantage with chemotherapy (median survival 12.5 in treatment group, 15.8 months in controls), although notably the 5-year survival was increased in the chemotherapy arm (26.4% compared with 14.9% in the observation arm). This study can be criticized as it was underpowered and the duration of chemotherapy suboptimal.
From 1998 to 2004, Oettle et al. [35] conducted a large multicenter phase 3 randomized trial to determine the influence of adjuvant gemcitabine chemotherapy after resection of pancreatic cancer on disease-free survival (CONKO-001). 386 patients were randomized to receive adjuvant chemotherapy with 6 cycles of gemcitabine (1,000 mg/m 2 by intravenous infusion during a 30-min period on days 1, 8 and 15 every 4 weeks; n = 179), or to observation following surgery only (n = 175). Early analysis identified a significant increase in median diseasefree survival with gemcitabine (13.4 months, 95% CI: 11.4-15.3) compared with controls (6.9 months, 95% CI: 6.1-7.8), but just failed to demonstrate a significant advantage in median overall survival (p = 0.06) with gemcitabine compared with control. In the final analysis [36] , median disease-free survival for the gemcitabine group was 13.4 months compared to 6.9 months for the observation arm (p ! 0.001). The estimated disease-free survival at 3 and 5 years was 23.5 and 16.0% in the gemcitabine group vs. 8.5 and 6.5% in the observation group, respectively. There was also a significant improvement in median overall survival with gemcitabine, 22.8 months, compared to observation alone, 20.2 months (p = 0.005).
Estimated overall survival at 3 and 5 years was 36.5 and 21.0% for gemcitabine patients versus 19.5 and 9.0% for observation patients, respectively. These results suggest a good chance of prolonged disease-free survival in patients undergoing R0 or R1 resections for pancreatic cancer.
In the ESPAC-1 study, patients were randomized to either chemotherapy or no chemotherapy. Chemotherapy was given intravenously for 6 months using bolus 5-FU. After a median of 47 months follow-up of patients in the 2 ! 2 factorial design, the median survival was 20.1 months (95% CI: 16.5-22.7) among the patients who received chemotherapy and 15.5 months (95% CI: 13.0-17.7) for the patients who did not receive chemotherapy (HR for death: 0.71, 95% CI: 0.55-0.92, p = 0.009; table 2 ). The 2-year survival estimate was 40% and 5-year survival 21% among patients who received chemotherapy and 30 and 8%, respectively, among patients who received no chemotherapy [24] .
Following the success of the ESPAC-1 trial in providing evidence for the use of adjuvant chemotherapy to improve survival in resected pancreatic cancer, the ESPAC group initiated the ESPAC-3 trial. This was an international multicenter phase 3 trial The aim was to recruit 330 patients into each arm of the trial, and recruitment began in June 2000. On publication of the ESPAC-1 results, however, it became apparent that there was a definite survival advantage for adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma over observation alone, and therefore the trial design was amended and the observation arm was dropped. The recruitment targets for the remaining 2 arms were increased to 515 patients each (a total of 1,030 patients with pancreatic ductal adenocarcinoma) and the trial was renamed to ESPAC-3(v2).
The trial closed having recruited a total of 1,583 patients, 1,088 of these with ductal adenocarcinoma. A meta-analysis compared patients from ESPAC-1 (2 ! 2), ESPAC-1 plus and a subgroup of patients from ESPAC-3(v1) [37] . The inclusion criteria for all groups were identical. A comparison was made between patients undergoing adjuvant chemotherapy with 5-FU/FA versus those receiving observation alone. A total of 225 patient were randomized to surgery alone, and 233 to adjuvant chemotherapy alone (no CRT). Median survival was 16. Subsequently the final analysis from ESPAC-3(v2) has been published in table 4 [31] . Data was shown from 1,088 patients from 16 countries randomized from July 2000 to Jan 2007 to either 5-FU/FA (n = 551) or gemcitabine (n = 537). After 34 months of follow-up, the median survival of resect-ed patients treated with 5-FU/FA was 23.0 months (95% CI: 21.1, 25.0) and 23.6 months for patients treated with gemcitabine (95% CI: 21.4, 26.4). There was no significant difference in survival estimates between the treatment groups on log-rank analysis ( 2 LR = 0.7; p = 0.39; HR GEM = 0.94; 95% CI: 0.81, 1.08). Resection margin status did not reveal any significant difference in the effect of treatment across subgroups (test of heterogeneity 2 1 = 0.3, p = 0.56). The authors concluded there was no significant difference in survival between adjuvant 5-FU/ FA and adjuvant gemcitabine. Saying that it was noted that there was a trend to improved survival for patients with node-positive disease or positive resection margins when gemcitabine was given. Also owing to the more favorable toxicity profile, gemcitabine was deemed the most appropriate choice for adjuvant therapy from this trial. The trial is now closed to recruitment and follow-up data is being collected for final analysis.
In 2009, Ueno et al. [38] further supported the use of gemcitabine. They randomized 119 patients into adjuvant gemcitabine (n = 57) versus observation (n = 62); patients were accrued over 3 years from 10 centers. There was a significantly longer disease-free survival in the gemcitabine arm (11.4 months vs. 5 months; p = 0.01). However, there was no improvement in overall survival with adjuvant gemcitabine (22.3 months vs. 19.4 months; p = 0.19), though it should be noted this study lacked power.
In the 2010 ASCO annual meeting, further trial data was presented in abstract form [39] . Bao et al. [40] presented a prospective phase 2 trial including 25 patients on gemcitabine and erlontinib for resected pancreatic cancer. Patients received gemcitabine (biweekly for 4 months) and erlontinib (daily for 12 months) within 10 weeks of surgery. 14 of 25 patients experienced disease recurrence though disease-free survival was 21.5 months (95% CI: 7.6-24.5 months). They noted the combination was tolerated moderately well with 1/3 requiring dose reduction/ holding during treatment.
Yamamoto et al. [41] published an analysis in 2010 of 73 patients undergoing resection for left-sided malignancies accrued between 1994 and 2007. They noted that 5-year survival for those treated with adjuvant gemcitabine was 51%, and on multivariate analysis administration of gemcitabine was shown to have an independent positive prognostic significance (p = 0.031). 
Meta-Analysis
Due to the relatively small numbers entered into the individual treatment groups in the ESPAC-1 trial, the differences between the 4 groups did not reach statistical significance; however, the advantage of adjuvant chemotherapy is maintained in a meta-analysis pooling the ESPAC data with data from smaller trials from Norway and Japan. This meta-analysis by Stocken et al. [42] aimed to investigate the roles of adjuvant CRT and chemotherapy following resection of pancreas ductal adenocarcinoma on overall survival. The meta-analysis included 5 randomized trials of adjuvant therapy. Individual patient data was available in 4 (875 patients) of the 5 selected randomized controlled trials (total number of patients with = 939). Assessment of adjuvant chemotherapy trials indicated a 25% significant reduction in the risk of death with chemotherapy (HR = 0.75; 95% CI: 0.64, 0.90; p = 0.001) with median survival estimated at 19.0 months (95% CI: 16.4, 21.1) with chemotherapy and 13.5 months (95% CI: 12.2, 15.8) without. The 2-and 5-year survival rates were estimated at 38 and 19%, respectively, with chemotherapy and 28 and 12% without. Conversely there was no significant difference between chemoradiation versus no chemoradiation to the risk of death (HR = 1.09; 95% CI: 0.89, 1.32; p = 0.43), with median survival estimated at 15.8 months (95% CI: 13.9, 18.1) and 15.2 months (95% CI: 13.1, 18.2), respectively. The 2-and 5-year survival rates were estimated at 30 and 12% with chemoradiation and 34 and 17% without.
In 2008, Boeck et al. [43] published a systematic review and meta-analysis of adjuvant chemotherapy in pancreatic cancer. Five trials were identified suitable to be included in the meta-analysis [23, [32] [33] [34] 36] , identifying a total of 482 treated patients and 469 controls. Median survival was increased by 3 months (95% CI: 0.3-5.7 months, p = 0.03) in the adjuvant chemotherapy group. There was a small increase of 3.1% in 5-year survival in the adjuvant chemotherapy group compared with controls (95% CI: -4.6 to 10.8%, p ! 0.05). The authors supported the use of adjuvant chemotherapy from this metaanalysis noting the statistically significant improvement in median survival.
A further meta-analysis published in 2009 by the ESPAC group reviewed the influence of resection margin status in the same patient population, concluding that resection margin involvement was not a significant factor for survival (HR: 1.10; 95% CI: 0.94, 1.29) [44] . The 2-and 5-year survival rate were 33 and 16%, respectively, for R0 patients and 29 and 15% for R1 patients. Adjuvant chemotherapy had a greater influence on survival in patients following an R0 resection compared with those having R1 resections, conferring a 7-month median survival benefit. The median survival was 20.8 months (95% CI: 17.7, 23.2) after R0 compared with 13.8 months (95% CI: 12.2, 16.4) after R1 resection, and 13.5 months (95% CI: 12.2, 15.8) after R0 but without chemotherapy. Chemoradiotherapy had the opposite effect on median survival after R1 resection: 14.7 months (95% CI: 11.5, 20.5) compared with 15.9 months (95% CI: 14.0, 18.5) after R0, and 11.2 months (95% CI: 9.4, 16.7) after R1 without adjuvant chemoradiotherapy. This meta-analysis suggests a possible beneficial effect of chemoradiotherapy in the subgroup of patients with positive resection margins.
Current Trials
ESPAC-4 is a phase 3, 2-arm, open-label, multicenter randomized clinical trial comparing combination gemcitabine and capecitabine therapy with gemcitabine alone when used as adjuvant therapy following resection for pancreatic adenocarcinoma. The main objective is to investigate whether combination chemotherapy (gemcitabine and capecitabine) when used in the adjuvant setting following resection of pancreatic adenocarcinoma improves survival over adjuvant therapy using gemcitabine alone. The trial is now open to recruitment and aims to recruit 1,080 patients (540 in each arm). It is anticipated that the trial will be completed in 2014.
In the US, a number of trials are currently investigating adjuvant CRT with the addition of new agents such as erlotinib, a tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor.
Using molecular targeted approaches combined with current agents may provide future avenues to further improve survival. One such recent study by Farrell et al. [45] investigated human equilibrative nucleoside transporter (hENT1) protein that transports gemcitabine into cells. The expression of hENT1 was assessed in 229 tissue microarrays acquired from resected pancreatic cancer specimens from the RTOG9704 trial. In those patients treated with gemcitabine adjuvant therapy, hENT1 expression was associated with increased overall survival and disease-free survival on univariate and multivariate analysis (HR: 0.40, 95% CI: 0.22-0.75, p = 0.004; and HR: 0.39, 95% CI: 0.21-0.73, p = 0.003). It is suggested that measuring hENT1 levels may have predictive value in determining which patients will respond to adjuvant gemcitabine.
Conclusions
There is now a significant level of evidence to support adjuvant chemotherapy in pancreatic cancer. The ESPAC-1 trial was instrumental in providing clear evidence for the role of adjuvant chemotherapy and the lack of benefit from chemoradiation in improving survival following resection in pancreatic cancer. These findings have not only shaped the delivery of adjuvant therapy in Europe, but affected the design of future European clinical trials such that they no longer include a chemoradiotherapy arm.
Using systemic chemotherapy in the adjuvant setting following resection of pancreatic cancer is now standard. The results of the CONKO-001 trial has added more weight to this argument. The ESPAC-3(v2) trial has demonstrated that there is no significant survival difference between adjuvant gemcitabine or 5-FU, and that the toxicity profiles of each would indicate that gemcitabine should be recommended above bolus 5-FU/FA.
The key to the future of adjuvant therapy in pancreatic cancer will be the identification of novel and effective agents, and better biomarker technology underpinned by translational research, which will inform the design of future trials. Ultimately this will ensure that patients will be able to receive targeted therapy to achieve the most benefit.
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